Eli Lilly

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Flag link:
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
3,500 Job Cuts at Eli Lilly Signal Change in Focus
3,500 Job Cuts at Eli Lilly Signal Change in Focus
Xconomy
Eli Lilly
layoffs
Flag link:
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Flag link:
Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
Marketwatch
Eli Lilly
migraines
clinical trials
galcanezumab
Flag link:
Drugmaker Lilly to trim workforce by nearly 9 percent
Drugmaker Lilly to trim workforce by nearly 9 percent
Yahoo/AP
Eli Lilly
layoffs
R&D
Flag link:
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Xconomy
Eli Lilly
rheumatoid arthritis
FDA
baricitinib
Flag link:
Pharma Stocks That Could Move On New Data
Pharma Stocks That Could Move On New Data
Barron's
pharma stocks
AbbVie
Bayer
Novartis
Bristol-Myers Squibb
Eli Lilly
European Society of Cardiology
Flag link:
Diabetes drugs must prove their value to payers, analysts say
Diabetes drugs must prove their value to payers, analysts say
Medical Marketing and Media
diabetes
payers
Novo Nordisk
semaglutide
Eli Lilly
Trulicity
Flag link:
3 Most Promising Cancer Drugs in Late-Stage Development
3 Most Promising Cancer Drugs in Late-Stage Development
Motley Fool
Eli Lilly
abemaciclib
advanced breast cancer
Incyte
epacadostat
Imbruvica
JNJ
prostate cancer
Flag link:
Eli Lilly: Can Sales Grow Without M&A?
Eli Lilly: Can Sales Grow Without M&A?
Barron's
Eli Lilly
M&A
Flag link:
Eli Lilly’s odyssey to use a fake rule and fake news to protect bad patents
Eli Lilly’s odyssey to use a fake rule and fake news to protect bad patents
Stat
Eli Lilly
patents
Canada
NAFTA
Strattera
Zyprexa
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
Lilly's turn to pain gathers momentum
Lilly's turn to pain gathers momentum
BioPharma Dive
Eli Lilly
Lasmiditan
migraines
Flag link:
Lilly's acute migraine drug succeeds in late-stage study
Lilly's acute migraine drug succeeds in late-stage study
Yahoo/Reuters
Eli Lilly
migraines
clinical trials
Lasmiditan
Flag link:
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
Fierce Pharma
formulary
Eli Lilly
Boehringer Ingelheim
JNJ
Invokana
diabetes
CVS Caremark
Flag link:
Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo
Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo
Fierce Pharma
Radius Health
Tymlos
Express Scripts
PBMs
formulary
Eli Lilly
Forteo
osteoporosis
Flag link:
Eli Lilly CEO expects a Trump executive order on drug pricing this year
Eli Lilly CEO expects a Trump executive order on drug pricing this year
CNBC
Eli Lilly
David Ricks
Pharma CEOs
drug pricing
Donald Trump
Flag link:
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Fierce Pharma
Eli Lilly
baricitinib
Pfizer
Xeljanz
bloodthinners
Flag link:
Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart
Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart
Endpoints
Eli Lilly
JNJ
AbbVie
WuXi
regenerative medicine
Rodeo Therapeutics
Flag link: